Rovi stock: Rovi reports on November 5, 2026. Rovi stock trades 1.32 percent below its close

Published on 10/19/2026 at 15:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi grew first-half 2026 revenue 13.20 percent on July 23, 2026. Rovi stock costs EUR 57.53 on October 19, 2026, 1.32 percent below the BME close.

Reporting date and valuation

Rovi will publish first nine months 2026 results on November 5, 2026.
First-half 2026 revenue rose 13.20 percent to EUR 357.00 million.
Rovi stock costs EUR 57.53 at Lang & Schwarz on October 19, 2026 at 3:36 p.m. CEST, 1.32 percent below the BME close of October 16, 2026.
Rovi has a price-to-earnings ratio of 15.83 and a dividend yield of 0.02 percent.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ISIN ES0157261019) is due to publish its first nine months 2026 financial results on November 5, 2026, according to Rovi. The stock was trading at EUR 57.53 at Lang & Schwarz on October 19, 2026 at 3:36 p.m. CEST, down 1.32 percent from the BME close of EUR 58.30 on October 16, 2026.

Revenue growth sets the baseline

Rovi reported total revenue growth of 13.20 percent in the first half of 2026, reaching EUR 357.00 million. The company also reported gross margin expansion of 6.50 percentage points in the period, giving investors two operating measures to compare with the nine-month update. The figures come from the investor information published by Rovi on July 23, 2026.

Rovi sits 33.64 percent below its high

The EUR 57.53 quote stands 8.34 percent above the 52-week low of EUR 53.10 and 33.64 percent below the 52-week high of EUR 86.70. Lang & Schwarz showed a bid of EUR 57.35 and an ask of EUR 57.70 at the same timestamp. Trading volume on the BME was 35,698 shares on October 19, 2026, against an average volume of 104,570 shares.

Valuation and November date

Rovi's market capitalization was EUR 2.9 billion on October 19, 2026. The finance snapshot gave the stock a price-to-earnings ratio of 15.83 and a dividend yield of 0.02 percent. The next scheduled company event is the publication of first nine months 2026 financial results on November 5, 2026, a date listed in Rovi's investor calendar.

Comparison with peers

Rovi (BME, EUR): minus 1.32 percent, P/E 15.83, market capitalization EUR 2.9 billion.

Grifols (BME, EUR): minus 2.10 percent, P/E 14.88, market capitalization EUR 6.8 billion.

Pharma Mar (BME, EUR): minus 0.29 percent, P/E 20.67, market capitalization EUR 1.2 billion.

Price remains the daily frame

Rovi's session quote places the company closer to its 52-week low than its high, while its valuation remains below the average market capitalization of the two comparison companies. The November 5 reporting date gives the next concrete checkpoint for the revenue and margin trends reported for the first half.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.